American scientists published the results of a one-year monitoring of participants in clinical trials concerning T-lymphocytes modified with chimeric antigen receptors for muscle stiffness syndrome.
It was noted that all patients showed sustained improvement in both general well-being and physical capabilities. Furthermore, 92 percent of these patients were able to do without continuous administration of immunotherapeutic agents.
These results were presented at the annual meeting dedicated to multiple sclerosis and other similar diseases, which was held under the name MSToronto2026, according to information published in a press release.